The question that changes the interpretation
Follow the metal to its next destination
Glutathione connects antioxidant enzymes, chemical conjugation and metal handling. Mitochondrial import creates a reserve that whole-cell measurements can miss. Some drugs use glutathione in parent-drug metabolism; others generate reactive metabolites that it neutralizes. A shared drug–metal vulnerability is experimentally plausible, but depends on species, compartment, exposure and replenishment. [1] [2] [3] [4]
One molecule, several distinct jobs
Glutathione is a small peptide assembled from glutamate, cysteine and glycine. Its cysteine sulfur makes it chemically useful, but “antioxidant,” “conjugating substrate” and “metal ligand” describe different reactions. In peroxide removal, glutathione peroxidases draw reducing equivalents from reduced glutathione, GSH, producing oxidized glutathione, GSSG. Glutathione reductase uses NADPH to regenerate GSH. A falling reduced pool therefore needs interpretation alongside recycling, synthesis and export; it is not simply an inventory of molecules irreversibly spent. [5]
Yang and colleagues made the enzyme dependence experimentally concrete: GSH-depleting compounds and direct GPX4 inhibitors converged on ferroptotic death in susceptible cancer cells. GPX4 manipulation altered those responses. GSH thus supports an enzyme that controls lipid hydroperoxides; calling it merely a free-radical scavenger misses that catalytic system. Iron dependence in ferroptosis does not mean every injured mitochondrion has released a stockpile of toxic metals. [6]
| Role | What happens | What would establish the consequence? |
|---|---|---|
| Redox/enzyme substrate | GSH supplies reducing equivalents; GSSG can be recycled. | Measure GSH/GSSG, NADPH and enzyme activity, with careful sample handling. [5] [6] |
| Organic conjugation | GSH forms a covalent conjugate with an electrophilic drug or metabolite. | Identify the conjugate and quantify parent/metabolite flux; detection alone does not establish depletion. [7] [8] |
| Metal coordination | Sulfur-containing ligands alter metal speciation and exchange. | Measure the metal–ligand species, competing ligands, transport and eventual elimination separately. [9] [10] |
Morgan and colleagues resolved Cu(I)–GSH coordination using controlled solution chemistry. Their work demonstrates why metal form, pH and ligand abundance matter. It does not turn GSH into a universal scavenger of every metal. Indeed, Maryon and colleagues found that lowering GSH reduced initial copper uptake through the human CTR1 system in cultured cells; restoring the pool restored uptake. A ligand can help receive and distribute an essential metal, not merely keep it out. Intracellular buffering also says nothing by itself about whether that metal leaves the body. [9] [10]
Mitochondria need delivery, not just a cellular supply
Wang, Yen, Zhu, Timson and colleagues identified SLC25A39 as necessary for mitochondrial GSH import in mammalian cells. Knockout lowered mitochondrial GSH while whole-cell GSH was preserved. Isotope-labelled GSH uptake into isolated mitochondria, genetic rescue and transport-site mutations supplied mechanistic evidence beyond correlation. SLC25A40 provided related, partly redundant capacity. The practical lesson for research is striking: a reassuring whole-cell assay can conceal a deficient organelle. [1]
Shi and colleagues independently connected SLC25A39 to the mitochondrial iron importer SLC25A37 using paired gene perturbations in K562 cells. Their interactions changed with the cells’ metabolic environment, linking GSH delivery, iron supply and oxidative phosphorylation. Liu and colleagues subsequently showed feedback through the mitochondrial protease AFG3L2 and an iron–sulfur-associated region of SLC25A39: GSH availability helps regulate transporter turnover. These discoveries make “reserve” a dynamic property of synthesis, recycling, delivery and demand, rather than a single blood or tissue concentration. [11] [12]
That architecture motivates a specific question: can a cell replenish cytosolic GSH while mitochondrial demand outruns import? This is a proposed explanation to test, not a demonstrated consequence of ordinary medicine use. It also predicts recovery and compensation; treating every conjugation event as a permanent loss ignores the adaptive machinery. [5] [1] [12]
Iron supply has potentially opposing consequences in this framework. It supports essential cofactor-dependent metabolism, yet poorly controlled availability can contribute to injury. A perturbation that improves cell survival in one growth medium may still compromise respiratory function in another. The paired-transporter studies therefore make functional readouts essential: a useful reserve model must explain energy production and recovery as well as survival, and it must specify the metabolic state in which its prediction holds. [11]
Iron, copper and cadmium do not tell the same story
Tsvetkov and colleagues identified a copper-dependent death mechanism involving copper binding to lipoylated metabolic proteins, their aggregation and loss of iron–sulfur proteins. GSH depletion increased copper-dependent vulnerability in their experimental systems. This supplies a reason to examine copper availability alongside mitochondrial reserve. It does not establish that every low-GSH state causes this pathway, or that copper toxicity and iron-dependent lipid peroxidation are interchangeable. [13] [6]
Cadmium provides a useful time-course warning. Nair and colleagues reported GSH loss during acute Cd(II) exposure of rat proximal-tubule cells, but both GSH and GSSG rose after subchronic exposure in rats, without a changed ratio. The designs differed, so this is not a controlled acute-versus-chronic comparison. It nevertheless defeats a simple diagnostic rule that metal injury must always coincide with low measured GSH. Compensatory synthesis, survival selection and compartment-specific changes remain possibilities requiring direct measurement. [14]
Which medicines actually require glutathione for clearance?
The answer is drug-specific, and sometimes yes. Busulfan is a clear example: its prescribing information describes predominant metabolism through GSH conjugation. Gibbs and colleagues demonstrated catalysis by human liver cytosolic glutathione S-transferases. Here GSH participates in processing the parent drug. That is different from mainly removing a small reactive branch product of another drug’s metabolism. Even this positive example establishes a metabolic route, not a general rule that GSH use makes a medicine dangerous. [2] [7]
Acetaminophen, also called paracetamol, is an analgesic and antipyretic; it is not conventionally an NSAID. Its principal metabolic routes are glucuronidation and sulfation. Oxidation produces the reactive metabolite NAPQI, which GSH can trap before it attacks cellular proteins. Thus, “glutathione is needed to detoxify NAPQI” is more precise than “acetaminophen is mainly cleared by glutathione.” Parent clearance, reactive-metabolite production and protective conjugation are related but separately measurable processes. [15] [3]
Exposure scale changes the interpretation. In Heard and colleagues’ randomized trial in selected healthy adults, repeated therapeutic acetaminophen administration caused aminotransferase elevations in some participants. Most persistent elevations resolved during continued administration, without the study’s bilirubin/INR evidence of liver dysfunction. The study did not measure metal movement or mitochondrial GSH. It therefore cannot demonstrate either a metal-mediated mechanism or the absence of every possible susceptibility; it does show why an enzyme biomarker alone should not be called progressive liver failure. [16]
NSAIDs are chemically heterogeneous. Tang and colleagues identified GSH-conjugated diclofenac metabolites in rat bile and cultured human hepatocytes, supporting reactive-metabolite formation and trapping. That does not show ordinary-use depletion, nor a class-wide NSAID effect. Bort and colleagues found early ATP impairment in diclofenac-exposed hepatocytes without an early detectable fall in GSH or rise in lipid peroxidation. Together with evidence that diclofenac itself can impair mitochondrial ATP synthesis, these findings caution against assigning all injury to GSH exhaustion and metal liberation. Unmeasured compartment-specific contributions remain possible. [8] [17]
| Exposure | Main distinction | Evidence boundary |
|---|---|---|
| Busulfan | GSH conjugation processes the parent drug. | Official pharmacology plus human liver enzyme experiments; metal co-exposure was not tested. [2] [7] |
| Acetaminophen | GSH traps NAPQI; most metabolism follows other routes. | Therapeutic use and overdose-type experimental injury must be separated. [3] [16] |
| Diclofenac | Reactive products can form GSH adducts. | One NSAID’s bioactivation is not a class-wide depletion result. [8] |
| Ethanol | ADH and ALDH perform the main oxidation sequence. | Chronic oxidant stress and mitochondrial GSH changes are additional questions. [18] [19] |
Ethanol is primarily converted to acetaldehyde by alcohol dehydrogenase and then to acetate by aldehyde dehydrogenase. GSH is not the principal reagent clearing ethanol. Chronic exposure can nevertheless alter defensive capacity. Fernández-Checa and colleagues measured impaired mitochondrial GSH uptake in chronic ethanol-fed rats. In a separate genetic mouse study, Lu and colleagues found less chronic ethanol-associated oxidant stress with CYP2E1 deletion and restoration with human CYP2E1 expression. Neither experiment measured a human drug–metal interaction, and the older transport study did not identify SLC25A39 as its molecular cause. [18] [19] [20]
One clinically relevant intersection is already explicit in busulfan prescribing information: acetaminophen-related lowering of GSH is presented as a possible reason for reduced busulfan clearance. The wording is conditional, not a measured universal interaction size. It illustrates the correct question—whether a specified exposure changes another drug’s pharmacokinetics under specified conditions—without turning a biochemical possibility into instructions to alter medication. [2]
A concrete bridge from drug injury to mobile iron
Hu and colleagues directly investigated iron redistribution during toxic acetaminophen exposure. Primary hepatocytes from fasted male C57BL/6 mice received 10 mM acetaminophen in culture. Compartment-sensitive fluorescence and interventions supported iron movement from lysosomal/endosomal stores into cytosol and mitochondria before depolarization. Lysosome-directed iron sequestration and inhibition of mitochondrial iron uptake reduced injury. The experiment supplies a causal model of iron amplification, with indirect probes and pharmacological limitations; it is not evidence that normal use releases environmental heavy metals in people. [4]
The initiating injury also matters. Xie and colleagues’ primary human hepatocyte work documented acetaminophen-associated protein adducts, JNK signalling and mitochondrial dysfunction under high experimental exposure. These findings fit a multistep injury network. An iron contribution need not replace reactive-metabolite toxicity, and an observed metal shift might amplify damage without being its original cause. Distinguishing those roles requires timed measurements and interventions that leave drug bioactivation intact. [21] [4]
The same resource can inform a pathogen
Glutathione also connects host physiology to microbial decisions. Reniere and colleagues showed that bacterial and host-derived GSH activate the virulence regulator PrfA in Listeria monocytogenes. In the 10403S strain background, genetic and biochemical experiments connected the signal to infection; an activated PrfA variant bypassed the requirement. This is a counterstrategy to remember when calling GSH a host defense: preserving host redox capacity and changing a pathogen’s behaviour are different outcomes. The finding does not justify assuming that every microbe responds similarly. [22]
Follow glutathione-associated cargo from liver to bile and intestine
A drug–metal reserve hypothesis that can fail
The proposed hypothesis is conditional: a defined metal exposure could increase injury from a defined drug when both stress a limited mitochondrial GSH supply, even before total cellular GSH falls substantially. It predicts an interaction beyond either exposure alone and a measurable sequence linking delivery failure to metal availability and function. It does not predict that all medicines, all metals or all low-GSH measurements carry the same risk. [1] [11] [4] [13]
A field note worth sharing
Normal total glutathione can conceal a mitochondrial shortfall, as SLC25A39 knockout experiments showed.
Drug–metal research should measure delivery and chemical species, not assume a whole-cell antioxidant measurement reveals every vulnerable pool. [1]
Demonstrated in experimental mammalian cell systems; this does not establish mitochondrial glutathione failure during ordinary medicine use.
Trace the central claims
Each claim carries its setting, source, and interpretation boundary. Experimental proposals are identified separately in the review.
Open the evidence ledger (17 claims)
| Claim | Evidence & setting | Boundary & source |
|---|---|---|
| GSH supports peroxide-reducing enzymes and can be regenerated from GSSG using NADPH. | established mechanism Mammalian biochemistry and cancer-cell perturbation | Review biochemical framework; Yang Figures 1–5 establish GPX4-specific cell-death relationships rather than universal mitochondrial protection. [5] [6] |
| GSH coordinates Cu(I) under controlled solution conditions. | observed Defined solution chemistry | Spectrophotometric–potentiometric titrations and phosphorescence; chemical speciation is not a measured excretion effect. [9] |
| Depleting GSH reduced initial CTR1-associated copper uptake in cultured cells. | model causal HEK293 and other cultured cells | Figures 4–6; rescue supports a GSH role but does not imply all cell types or whole-body copper balance respond identically. [10] |
| SLC25A39 loss can lower mitochondrial GSH without reducing whole-cell GSH. | model causal Human cell lines and isolated mitochondria | Figure 2; genetic perturbation and isotope uptake. No routine drug exposure. [1] |
| SLC25A39 and SLC25A37 interact in support of mitochondrial function. | model causal K562 cells in defined metabolic media | Figures 3–5; environment-dependent genetic interaction, not a clinical exposure association. [11] |
| AFG3L2-mediated SLC25A39 turnover participates in GSH-responsive feedback. | model causal Cell and biochemical experiments | Figures 1–4; iron–sulfur-associated regulatory interpretation remains bounded to the tested system. [12] |
| Copper-dependent death can involve lipoylated protein aggregation and Fe–S protein loss. | model causal Human cancer cell models with mouse comparison | Figures 4–6; GSH depletion arm is experimental. Verified erratum 10.1126/science.abq4855 concerns Figure 4C, Table S2 completeness and a figure callout; no correction to the cited GSH/lipoylation findings is described. Coordinator provenance records the notice. [13] |
| Acute cell exposure and subchronic rat exposure produced different GSH patterns. | observed Rat proximal-tubule cells and Fischer 344 rats | Abstract only; differing models/routes prevent treating the contrast as a matched longitudinal experiment. [14] |
| Busulfan parent-drug metabolism prominently uses GSH conjugation. | established mechanism Official human pharmacology and human liver enzyme study | Label section 12.3; Gibbs abstract. The APAP interaction in section 7.1 is conditional, not quantified here. [2] [7] |
| Acetaminophen mainly undergoes glucuronidation/sulfation; GSH detoxifies NAPQI. | established mechanism Human clinical pharmacology | Label Metabolism and Excretion; does not mean GSH is the main parent-clearance route. [3] |
| Acetaminophen is not conventionally classified as an NSAID. | established mechanism Official drug classification | FDA brochure separates acetaminophen from NSAIDs; classification claim rather than an intervention. [15] |
| Some ALT elevations resolved during continued therapeutic acetaminophen administration without measured liver dysfunction. | human intervention Selected healthy adult volunteers | Results/Figures 2–4; no direct GSH or metal measurements, exclusion criteria limit generalization. [16] |
| Diclofenac can produce reactive intermediates trapped as GSH conjugates. | observed Rat bile and human hepatocyte cultures | Abstract only; does not demonstrate ordinary-use depletion or a class-wide NSAID effect. [8] |
| ADH/ALDH oxidation is distinct from chronic ethanol-associated effects on mitochondrial GSH and CYP2E1 stress. | established mechanism Human metabolic framework; rat and mouse mechanistic studies | Official metabolism page plus primary-study abstracts. Humanized CYP2E1 mice are not a human intervention; no inference of ethanol GSH-conjugation clearance. [18] [19] [20] |
| Toxic acetaminophen exposure can mobilize chelatable iron toward mitochondria and amplify injury. | model causal Fasted male C57BL/6 primary mouse hepatocytes; 10 mM culture APAP | Figures 2–4; indirect probes and pharmacological interventions. Not human therapeutic exposure. [4] |
| GSH can activate the Listeria PrfA virulence regulator. | model causal L. monocytogenes 10403S background and infection models | Figures 1–4 and Methods; strain/pathogen-specific evidence, not a generic microbiome prediction. [22] |
| A drug–metal interaction could depend on limited mitochondrial GSH delivery rather than total-cell depletion. | hypothesis Proposed factorial human hepatocyte experiments | Editorial synthesis; no cited study establishes the full clinical co-exposure chain. Import restoration, metal timing and matched drug metabolism are required discriminators. [1] [11] [4] [13] |
Questions worth asking
Is glutathione a metal chelator or an antioxidant?
It can participate in both metal coordination and redox chemistry, while also serving as an enzyme substrate and forming organic conjugates. The reaction, metal species, location and subsequent transport determine the effect; binding alone does not prove elimination.
Are all medicines that use glutathione risky because they deplete it?
No. Using a metabolic substrate does not establish depletion or injury. The important variables include the fraction using that route, reactive-product formation, replenishment, compartmental delivery and measured outcomes. Busulfan parent metabolism and acetaminophen NAPQI detoxification illustrate different cases.
Does a normal whole-cell glutathione result exclude mitochondrial deficiency?
No. Experimental SLC25A39 loss separates mitochondrial from whole-cell GSH. This compartment distinction does not validate a routine clinical test for mitochondrial reserve.
Does acetaminophen injury prove that drugs release heavy metals?
The evidence concerns endogenous iron in a toxic-exposure mouse-cell model. It does not establish ordinary-use human effects or a universal metal-release mechanism.
Sources & further reading
Sources supporting the numbered claims. This is a narrative research synthesis. Each study’s model and the limits of its interpretation are recorded in the evidence ledger; proposed experiments are editorial analysis.
- Wang Y, Yen FS, Zhu XG, Timson RC et al. (2021). SLC25A39 is necessary for mitochondrial glutathione import in mammalian cells. View source↩↩↩↩↩↩↩↩
Study setting & source access
CRISPR perturbation, organelle metabolomics and isotope uptake. Human K562, HEK293T and HeLa cells; additional mouse genetic experiments
Figure 2: organelle metabolomics, isotope uptake and genetic rescue. Cell-line evidence; no routine drug exposure tested.
Source access: full text · primary
- Meitheal Pharmaceuticals Inc. / DailyMed (2021). BUSULFAN injection, solution — prescribing information. View source↩↩↩↩↩
Study setting & source access
Official prescribing information. Human drug pharmacology
Sections 12.3 and 7.1. Parent-drug conjugation is established; the acetaminophen interaction is phrased conditionally, without an effect size.
Source access: full text · guidance
- DailyMed (2026). ACETAMINOPHEN injection, solution — prescribing information. View source↩↩↩↩
Study setting & source access
Official prescribing information. Human clinical pharmacology
Metabolism and Excretion section; official record dated 2026-03-20. No metal co-exposure experiment.
Source access: full text · guidance
- Hu J, Kholmukhamedov A, Lindsey CC, Beeson CC, Jaeschke H, Lemasters JJ (2016). Translocation of iron from lysosomes to mitochondria during acetaminophen-induced hepatocellular injury: Protection by starch-desferal and minocycline. View source↩↩↩↩↩↩↩
Study setting & source access
Compartment-sensitive imaging and pharmacological perturbation. Primary hepatocytes from overnight-fasted male C57BL/6 mice, directly exposed to 10 mM acetaminophen in culture
Methods and Figures 2–4. Toxic culture exposure; indirect iron probes and pharmacological interventions. No human therapeutic-exposure or environmental-metal-release experiment.
Source access: full text · primary
- Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009). Glutathione dysregulation and the etiology and progression of human diseases. View source↩↩↩↩
Study setting & source access
Mechanistic synthesis. Glutathione metabolism across mammalian experimental systems
Background for synthesis, NADPH-dependent recycling and conjugate export; review, not a drug–metal intervention study.
Source access: full text · review
- Yang WS et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. View source↩↩↩↩
Study setting & source access
Chemical genetics, metabolomics and GPX4 perturbation. Human cancer cell lines including HT-1080 and BJeLR, with mouse xenograft experiments
Figures 1–5 distinguish GSH-depleting compounds from direct GPX4 inhibitors. Cell death responses are model- and compound-specific.
Source access: full text · primary
- Gibbs JP, Czerwinski M, Slattery JT (1996). Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. View source↩↩↩↩
Study setting & source access
Biochemical human liver fraction and recombinant enzyme study. Human liver cytosol, microsomes, purified GST and cDNA-expressed GST-alpha 1-1
Abstract: cytosol catalyzed GSH-busulfan tetrahydrothiophenium formation; microsomes lacked activity under assay conditions. Supports direct parent-drug conjugation, not a human metal co-exposure result. Article Cancer Research 56(16):3678–3681.
Source access: abstract · primary
- Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, Strauss JR, Kwei GY, Rushmore TH, Chiu SH, Baillie TA (1999). Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. View source↩↩↩↩
Study setting & source access
LC-MS/MS metabolite identification plus microsomal and hepatocyte experiments. Sprague-Dawley rat bile after single intraperitoneal diclofenac exposure; rat liver microsomes; human hepatocyte cultures
Abstract only: metabolite identification in rat bile and cultured human hepatocytes; no ordinary-use depletion or class-wide NSAID inference.
Source access: abstract · primary
- Morgan MT, Nguyen LAH, Hancock HL, Fahrni CJ (2017). Glutathione limits aquacopper(I) to sub-femtomolar concentrations through cooperative assembly of a tetranuclear cluster. View source↩↩↩
Study setting & source access
Solution coordination chemistry. Cu(I)–glutathione equilibria, spectrophotometric–potentiometric titrations and low-temperature phosphorescence
Chemical speciation under controlled pH and ligand/metal ratios; does not directly establish the dominant complex in every living compartment or metal excretion.
Source access: full text · primary
- Maryon EB, Molloy SA, Kaplan JH (2013). Cellular glutathione plays a key role in copper uptake mediated by human copper transporter 1. View source↩↩↩
Study setting & source access
Radiotracer uptake and glutathione perturbation. HEK293 cells expressing human CTR1 and additional cultured cell lines
Figures 4–6: GSH depletion reduced initial 64Cu uptake; washout or GSH-ester restoration reversed the effect. This is uptake biology, not proof of net body elimination.
Source access: full text · primary
- Shi X, Reinstadler B, Shah H et al. (2022). Combinatorial GxGxE CRISPR screen identifies SLC25A39 in mitochondrial glutathione transport linking iron homeostasis to OXPHOS. View source↩↩↩↩↩
Study setting & source access
Paired CRISPR screening and mitochondrial functional assays. Human K562 cells in four culture environments, organelle metabolomics and uptake assays
Figures 3–5: interaction with SLC25A37 depends on metabolic environment. Not a human drug–metal exposure study.
Source access: full text · primary
- Liu Y, Liu S, Tomar A et al. (2023). Autoregulatory control of mitochondrial glutathione homeostasis. View source↩↩↩
Study setting & source access
Genetic, proteomic and biochemical perturbations. Mammalian cell culture and isolated mitochondria
Figures 1–4: AFG3L2-mediated SLC25A39 turnover and cysteine/iron–sulfur-linked regulation. Experimental feedback does not ensure unlimited reserve.
Source access: full text · primary
- Tsvetkov P, Coy S, Petrova B et al. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. View source↩↩↩↩
Study setting & source access
Chemical/genetic screens and mechanistic cell-death experiments. Human cancer cell lines, copper ionophore and transporter manipulations; Atp7b-deficient mouse liver comparison
Figures 4–6; experimental copper/GSH mechanisms, not ordinary analgesic-use evidence. The coordinator verified publisher erratum 10.1126/science.abq4855: replacement of the representative low-FDX1 tumor image in Figure 4C (Figure 4B quantitative data stated correct), addition of missing disulfiram/cupri-DDC screen datasets to Table S2, and serum-copper callout S1Q→S1D. No correction to the cited GSH or lipoylation findings is described.
Source access: full text · primary
- Nair AR, Lee WK, Smeets K, Swennen Q, Sanchez A, Thévenod F, Cuypers A (2015). Glutathione and mitochondria determine acute defense responses and adaptive processes in cadmium-induced oxidative stress and toxicity of the kidney. View source↩↩
Study setting & source access
Cell exposure and subchronic animal experiment. Rat WKPT-0293 Cl.2 proximal-tubule cells and Fischer 344 rats
Abstract: acute cultured-cell Cd(II) exposure lowered GSH; subchronic rat exposure increased both GSH and GSSG without changing their ratio. Different exposure routes and time scales prevent direct numerical comparison.
Source access: abstract · primary
- U.S. Food and Drug Administration (n.d.). The best way to take your over-the-counter pain reliever? Seriously. (Four Panel Brochure). View source↩↩
Study setting & source access
Official public drug information. Human OTC analgesics
What are pain relievers/fever reducers? explicitly separates acetaminophen and NSAID categories, lists aspirin/naproxen/ketoprofen/ibuprofen under NSAIDs. No reliable publication date visible; accessed 2026-10-02. Statements about ordinary directed use and excess exposure should remain distinct.
Source access: full text · guidance
- Heard K, Green JL, Anderson V, Bucher-Bartelson B, Dart RC (2014). A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. View source↩↩↩
Study setting & source access
Randomized placebo-controlled human trial. Healthy adults with normal baseline liver testing; repeated acetaminophen exposure for at least 16 days with extension to 40 days for unresolved elevations
Results/Figures 2–4. Selected healthy adults, attrition and exclusion criteria limit generalization; metals/GSH not measured. Investigator-initiated McNeil funding; sponsor reported no conduct/analysis role.
Source access: full text · primary
- Bort R, Ponsoda X, Jover R, Gómez-Lechón MJ, Castell JV (1999). Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. View source↩
Study setting & source access
Comparative cell toxicity and metabolism experiments. Human and rat primary hepatocytes, HepG2 and FaO cells
Abstract: ATP decline preceded overt injury; early GSH decline/lipid peroxidation were not detected. Drug itself impaired mitochondrial ATP synthesis, with additional metabolism-dependent toxicity. Useful against universal GSH-depletion/metal-release explanation; no proof of ordinary-dose patient toxicity. JPET 288(1):65–72.
Source access: abstract · primary
- National Institute on Alcohol Abuse and Alcoholism (n.d.). Alcohol Metabolism. View source↩↩↩
Study setting & source access
Official public science information. Human ethanol metabolism
The Chemical Breakdown of Alcohol: ADH converts ethanol to acetaldehyde and ALDH converts acetaldehyde to acetate. Supports primary clearance distinction, not a direct GSH-conjugation mechanism. No reliable publication date visible; accessed 2026-10-02. Avoid reproducing the page’s oversimplified statement that CYP2E1 is only active after large alcohol amounts; use a primary chronic exposure study for CYP2E1 mechanisms.
Source access: full text · guidance
- Fernández-Checa JC, García-Ruiz C, Ookhtens M, Kaplowitz N (1991). Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats. Tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. View source↩↩↩
Study setting & source access
Tracer kinetics, subcellular fractionation, oxidant challenge and GSH-ester rescue. Livers and isolated hepatocytes from chronic ethanol-fed rats versus controls
Abstract only: chronic ethanol-fed rat tracer/oxidant experiments. Does not identify SLC25A39 or demonstrate a human metal interaction.
Source access: abstract · primary
- Lu Y, Wu D, Wang X, Ward SC, Cederbaum AI (2010). Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. View source↩↩
Study setting & source access
Genetic knockout and human CYP2E1 knock-in comparison with pair feeding. Wild-type, CYP2E1-null and humanized CYP2E1 knock-in mice fed high-fat Lieber-DeCarli ethanol diet for three weeks
Abstract: oxidant stress/steatosis blunted in knockout and restored in knock-in mice; more marked injury in knock-ins accompanied higher human CYP2E1 levels than mouse CYP2E1 in WT. Humanized enzyme does not make this a human clinical study. Supports chronic model mechanism, with expression-level limitation. DOI 10.1016/j.freeradbiomed.2010.07.026.
Source access: abstract · primary
- Xie Y, McGill MR, Dorko K, Kumer SC, Schmitt TM, Forster J, Jaeschke H (2014). Mechanisms of acetaminophen-induced cell death in primary human hepatocytes. View source↩↩
Study setting & source access
Primary human hepatocyte exposure and pharmacological perturbation. Freshly isolated human hepatocytes from donor/resected livers, 44 preparations in total; high millimolar APAP exposure
Relevant indexed PMC full-text Methods/Results/Discussion read (direct opens hit CAPTCHA). Table 1 describes donors; Figure 3 measures GSH, membrane potential and adducts; Figure 4 shows JNK activation/translocation; inhibitor experiments reduce injury. Supports protein-adduct/JNK/mitochondrial pathway in an overdose-type cell model, not ordinary therapeutic exposure or an exhaustive mechanism. DOI 10.1016/j.taap.2014.05.010.
Source access: full text · primary
- Reniere ML, Whiteley AT, Hamilton KL et al. (2015). Glutathione activates virulence gene expression of an intracellular pathogen. View source↩↩
Study setting & source access
Bacterial genetics, biochemical binding and infection experiments. Listeria monocytogenes 10403S background, mammalian cell infection and mice
Figures 1–4; 10403S bacterial background and infection models. Pathogen-specific regulation, not a general microbiome response.
Source access: full text · primary
Cite this page
Karen Pendergrass. Glutathione, metals and the mitochondrial reserve. 2026-10-02. https://microbialmetallomics.com/library/glutathione-metals-mitochondria-drug-metabolism
Published at https://microbialmetallomics.com/library/glutathione-metals-mitochondria-drug-metabolism